Acquisition - May 26, 2014
Bringwell sells NaturaMed Pharma
Bringwell is selling its subsidiary NaturaMed Pharma to Volato for SEK 308 million. NaturaMed Pharma is a supplier of food supplements, pharmaceuticals and health care and athletic products sold directly to customers. The payment settlement will be made in cash and will be used to reimburse the company’s debts, meaning that Bringwell will become debt […]
Drug Development Pharma - May 26, 2014
EU approves Eli Lilly-Boehringer diabetes drug
The European Commission has granted marketing authorization for Jardiance (empagliflozin) tablets. It is a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of type 2 diabetes mellitus (T2D) to improve glycemic control in adults in Europe. The European Commission approved JARDIANCE 10 and 25 mg once daily tablets for use when diet and exercise […]
Uncategorized - May 23, 2014
Gene behind unhealthy adipose tissue identified
Researchers at Karolinska Institutet in Sweden have for the first time identified a gene driving the development of pernicious adipose tissue in humans. The findings imply, which are published in the scientific journal Cell Metabolism, that the gene may constitute a risk factor promoting the development of insulin resistance and type 2 diabetes. Adipose tissue […]
Drug Development Pharma - May 23, 2014
CHMP says no to Laquinimod
Teva Pharmaceutical and Active Biotech has announced that the Committee for Medicinal Products for Human Use’s confirmed its earlier opinion to recommend against approval for the treatment of relapsing-remitting multiple sclerosis in the European Union at this time. According to a statement from Active Biotech, both companies remain committed to the NERVENTRA (laquinimod) clinical development program for […]
Clinical Trials - May 22, 2014
Immunicum presents data from phase I/II study
Immunicum has announced continued compelling survival data from its phase I/II-study in metastatic renal cell carcinoma. The data showed a median survival for patients with poor prognosis (five patients) currently at 13 months compared to the expected median survival of 8-9 months for patients treated with tyrosine kinase inhibitors. One patient was excluded from the survival study […]
Collaboration - May 22, 2014
Collaboration between MSD and Stockholm County Council
The pharmaceutical company MSD has signed collaboration agreement with the Stockholm County Council. The parties have signed a letter of intent with the aim to achieve better quality of health care in Stockholm, especially regarding therapy areas where there is a growing need for improved treatment or diagnostics. “In Sweden there is a unique health […]
